View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 24, 2021updated 01 Nov 2021 8:53am

GE Healthcare to acquire surgical visualisation firm BK Medical for $1.45bn

The takeover will extend GE Healthcare’s ultrasound portfolio into surgical visualisation and boost growth in precision health.

GE Healthcare has signed an agreement to acquire surgical visualisation firm BK Medical from Altaris Capital Partners for $1.45bn in cash.

BK Medical develops intraoperative imaging and surgical navigation tools, which help guide doctors during robotic or less invasive surgical procedures.

Additionally, deep tissue can be visualised during procedures in neuro and abdominal surgery as well as in ultrasound urology.

GE Healthcare noted that the BK Medical takeover supports the expansion of its $3bn ultrasound business from diagnostics into surgical and therapeutic interventions.

GE Healthcare president and CEO Kieran Murphy said: “Ultrasound today forms an integral part of many care pathways, and BK Medical is a strategic and highly complementary addition to our growing and profitable Ultrasound business.

“This transaction helps GE Healthcare continue to expand beyond diagnostics into surgical and therapeutic interventions, simplifying decision-making for clinicians and equipping them with greater insights to deliver faster, more personalised care for their patients – representing another step toward delivering precision health.”

The acquisition will further strengthen BK Medical, including through substantial collaborations leveraging GE’s technology and commercial scale.

Furthermore, the deal will offer BK Medical’s Active Imaging platform to new users and markets across the globe.

Merging the diagnostic imaging technology of GE with BK’s expertise in enabling decision-making and surgical visualisation is hoped to extend the care continuum.

GE Healthcare anticipates BK Medical to provide quick revenue, margin growth and increased free cash flow.

The company also estimates the acquisition to deliver a high-single-digit return on invested capital by the fifth year.

Subject to review by regulatory agencies, the acquisition is anticipated to conclude next year.

In July, GE Healthcare and SOPHiA GENETICS signed a letter of intent to work together on targeting and matching treatments that can suit individual patient’s genomic profile and cancer type.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Medical Device Network